Both carotid endarterectomy (CEA) and carotid artery stenting (CAS) are common treatments for carotid artery stenosis. Several randomized controlled trials (RCTs) have compared CEA to CAS in the treatment of carotid artery stenosis. These studies have suggested that CAS is more strongly associated with periprocedural stroke; however, CEA is more strongly associated with myocardial infarction. Published longterm outcomes report that CAS and CEA are similar. A reduction in complications associated with CAS has also been demonstrated over time. The symptomatic status of the patient and history of previous CEA or cervical radiotherapy are significant factors when deciding between CEA or CAS. Numerous carotid artery stents are available, varying in material, shape and design but with minimal evidence comparing stent types. The role of cerebral protection devices is unclear. Dual antiplatelet therapy is typically prescribed to prevent in-stent thrombosis, and however, evidence comparing periprocedural and postprocedural antiplatelet therapy is scarce, resulting in inconsistent guidelines. Several RCTs are underway that will aim to clarify some of these uncertainties. In this review, we summarize the development of varying techniques of CAS and studies comparing CAS to CEA as treatment options for carotid artery stenosis.
| INTRODUC TI ON
Approximately 6.5 million strokes occur per year.
1 Stroke is the second-leading cause of death and is the leading cause of premature mortality and morbidity for both men and women. 1, 2 Atherosclerotic carotid artery stenosis is responsible for ~20% of strokes, typically occurring at the bifurcation of the internal and external carotid arteries. 3, 4 Unfortunately, carotid atherosclerosis is often asymptomatic until a disabling or fatal stroke occurs.
Patients with vascular disease and risk factors such as diabetes mellitus, hypertension, hyperlipidaemia and smoking are at significantly higher risk of developing carotid artery atherosclerosis.
Not all patients with carotid atherosclerosis are at increased risk of stroke; however, a strong association between severity of stenosis and stroke risk exists. Clinically important stenosis (the point at which the stroke risk is increased) varies between guidelines but is generally defined as stenosis >50% or >60%. The prevalence of clinically significant carotid artery stenosis is ~0%-1% in the general population and ~1% in persons ≥65 years of age. 5 The prevalence of severe asymptomatic carotid artery stenosis (>70%) is as high as 3.1%. 6 Carotid artery stenosis can be treated medically or surgically to prevent stroke or stroke-related death. Treatment of carotid stenosis reduces stroke risk and stroke-related morbidity and mortality. 3 Carotid endarterectomy (CEA) and carotid artery stenting (CAS) are commonly used to treat carotid stenosis. CEA was first described by DeBakey in 1975 who reported successful use of this procedure in the 1950s. CEA has become conventional treatment for carotid artery stenosis.
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In this review, the history, techniques and trial data concerning the emergence and evolution of CAS as an alternative to CEA are comprehensively examined.
| EMERG EN CE OF ENDOVA SCUL AR MANAG EMENT OF C AROTID ARTERY S TENOS IS
Endovascular treatment as an alternative to CEA emerged following trials demonstrating the benefit of angioplasty and stenting in patients with coronary artery disease. Since its first reported use for an intimal flap in 1989, a number of randomized controlled trials (RCTs) have demonstrated the long-term safety and efficacy of CAS for carotid stenosis. 8, 9 Cost-effectiveness and its use in surgically inaccessible lesions made CAS an attractive prospect. 24 Since its inception, the technological aspects of endovascular treatment for carotid artery stenosis have evolved significantly; however, this has come at the expense of its financial benefit. 25 
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Complications such as plaque dislodgement, intimal dissection, elastic vessel recoil and late restenosis are thought to be more likely with angioplasty compared to CAS. 26 Although no trials have evaluated stenting vs angioplasty alone, primary stenting is accepted as the endovascular technique of choice for carotid stenosis and has generally replaced balloon angioplasty.
| C A S VS CE A IN C AROTID ARTERY S TENOS IS
Since the emergence of endovascular approaches, the preferred management of carotid artery stenosis has been widely debated. A large number of RCTs have attempted to evaluate which treatment is superior. Results of these studies show that periprocedural stroke is more common with CAS (particularly in symptomatic patients), while myocardial infarction (MI) is more common with CEA. The heterogenous definitions of the MI endpoint in these studies have been a point of contention amongst the stroke community. Clinically silent ischaemic lesions are also more commonly associated with CAS despite being of uncertain clinical significance. 27, 28 Nevertheless, similar long-term outcomes with CAS and CEA have been reported in most RCTs and appear to be a statistically sound observation.
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The WALLSTENT trial in 2001 was the first RCT to compare CAS with CEA; however, this was prematurely terminated due to high complication rates in the stenting arm. 30 Though small, the first RCT to demonstrate that CAS produced outcomes comparable to CEA was published that same year. 31 Since then, larger trials have demonstrated the safety and efficacy of CAS compared to CEA (Table 1) .
| Randomized controlled trials: mixed cohorts
The CAVATAS study (n = 504) was the first multicentre RCT to suggest that endovascular management of carotid stenosis may be non-inferior to CEA; however, wide confidence intervals make interpretation of some data difficult. 9,10 Similar periprocedural and long-term stroke, death and restenosis rates between groups were reported; however, significantly more postoperative cranial nerve injuries (CNIs) and major groin/neck haematomas occurred with CEA. Patients in the endovascular arm who received a stent (n = 50)
had significantly lower risk of restenosis compared to those undergoing balloon angioplasty alone (n = 145).
The CREST trial is the largest international RCT comparing CEA to CAS (n = 2502) in a cohort of both symptomatic and asymptomatic patients. 12, 13 Periprocedurally, the stroke/death/MI rate did not differ significantly between groups although individual rates of periprocedural stroke, death and MI did differ. For example, significantly more periprocedural strokes occurred with CAS, but there were fewer periprocedural MIs. CNIs were more common with CEA.
Ten-year follow-up data reported no significant difference in the stroke/death/MI rates between the groups. Similar long-term results were seen with respect to postprocedural ipsilateral stroke, although periprocedural stroke/death and subsequent ipsilateral stroke numbers favoured CEA. This is attributable to periprocedural differences. No significant difference was seen between the two treatment groups with respect to restenosis or need for revascularization.
The SAPPHIRE trial (n = 334) is the only large multicentre RCT comparing CAS to CEA in "high-risk" patients (defined as clinically significant cardiac disease, severe pulmonary disease, contralateral carotid occlusion or laryngeal-nerve palsy, previous radical neck surgery or cervical radiotherapy (c-XRT), recurrent stenosis after CEA and age >80). 14, 15 Over 70% of participants had asymptomatic stenosis. It reported non-inferiority of CAS with respect to periprocedural death/stroke/MI or postprocedural death/ipsilateral stroke;
however, these incidences were notably high. No significant differences in periprocedural death/stroke/MI or death/ipsilateral stroke between 31 days and 3 years and long-term restenosis were seen between groups. Whether patients who are "high risk" according to SAPPHIRE criteria have poorer outcomes with CEA has been disputed. 32 Whether some of these patients required surgical or endovascular therapy has also been questioned.
| Prospective non-randomized registries: mixed cohorts
The CaRESS study was a multicentre, prospective, nonrandomized trial (n = 397) that supported the results of CREST and CAVATAS. 33, 34 There were no significant differences in death/stroke rates at 30 days, 1 year or 4 years between CEA and CAS groups. When analysed individually, rates of stroke and death at 4 years were similar. No significant difference in rates of death/MI/non-fatal stroke at 30 days, 1 year or 4 years was reported. In comparison with CREST, restenosis was more common with CAS; however, revascularization rates were similar between groups (P = 0.263).
| Randomized controlled trials: symptomatic carotid artery stenosis
Trials targeting symptomatic patients generally favour CEA over CAS. 35 ICSS is the largest RCT comparing CAS with CEA in patients with symptomatic carotid artery stenosis (n = 1713). 21, 22 The incidence of stroke/death/MI within 120 days of treatment was higher with CAS, as were 5-year stroke rates. Most strokes in this time period were non-disabling as 5-year rates of fatal/disabling strokes were similar. The combined outcome of procedure-related stroke/ death or ipsilateral stroke during follow-up was also more frequent with CAS. Again, significantly more CNIs and haematomas occurred with CEA. Long-term rates of restenosis or occlusion did not differ between groups.
More unfavourable results were seen in the EVA-3S study, a multicentre non-inferiority RCT with a median follow-up of 7.1 years (n = 527). 18, 19 Exceptionally high rates of periprocedural stroke/ death with CAS led to the trial being stopped prematurely. This also CNI, cranial nerve injury; EPD, embolic protection device; MI, myocardial infarction.
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death and non-procedural ipsilateral stroke were significantly higher with CAS, 10-year results were not significantly different. High rates of periprocedural stroke/death with CAS accounted for this, with similar postprocedural stroke numbers between groups. No significant difference was seen in restenosis rates.
Similar results arose from the SPACE study, another large multicentre international RCT (n = 1200). 16, 17 Non-inferiority of CAS was not demonstrated with respect to periprocedural death/ipsilateral ischaemic stroke. Rates of ipsilateral ischaemic stroke at 2 years and periprocedural stroke/death were similar between groups.
Recurrent stenosis was more frequent with CAS. Subgroup analysis of the CREST trial revealed no difference in periprocedural stroke/ death/MI rates or long-term postprocedural ipsilateral stroke rates based on symptomatic status.
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| Randomized controlled trials: asymptomatic carotid artery stenosis
A lack of evidence makes the utility of CAS in asymptomatic patients uncertain. The Asymptomatic Carotid Trial (ACT-1) is the only multicentre RCT comparing CEA and CAS in asymptomatic patients (n = 1453). 23 CAS was reported as non-inferior to CEA with respect to combined periprocedural death/stroke/MI or ipsilateral stroke within 1 year (3.8% vs 3.4%, respectively). Some consider these rates somewhat high for what is thought to be a low-risk cohort, although these are the lowest reported complication rates to date. Both periprocedural stroke and death rates and postprocedure stroke rates up to 5 years were similar between groups, as were cumulative 5-year rates of stroke-free survival. This was also a sponsored study. As mentioned, no difference in periprocedural stroke/ death/MI rates or long-term postprocedural ipsilateral stroke rates based on symptomatic status in the CREST trial. 12, 13 Interim results from the ongoing ACST-2 trial report a 1% rate of periprocedural disabling stroke, fatal MI and death in all included participants. 36 RCTs performed in the 1990s showed that prophylactic CEA plus medical therapy provided better outcomes than medical therapy alone. 37 Several medications that are now considered best medical therapy (BMT), such as statins, were not available or in widespread use at the time of these trials, and hence, these results may no longer be applicable. Annual stroke rates in asymptomatic carotid artery stenosis have been reported as low as <1% with modern BMT.
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BMT is now considered the gold standard for asymptomatic carotid artery stenosis in some guidelines. There is likely to be a small subset of patients with asymptomatic stenosis who are at high risk of stroke that would benefit from revascularization; however, the criteria to identify these patients have not been clearly established.
| Complications associated with CAS and CEA
Periprocedural stroke is more likely with CAS; however, this difference has reduced with time ( Figure 2A ). In fact, CREST reported the fewest periprocedural complications compared to other RCTs.
Overall, this trend may reflect the increasing skill of proceduralists, the need for credentialing and emerging endovascular techniques and technologies. Thus, results from earlier RCTs may be less applicable. Additionally, periprocedural stroke after carotid revascularization is not always secondary to thromboembolism and often occurs due to haemodynamic disturbance. 39 MI is more common with CEA, likely due to the periprocedural anaesthetic risk, as are
CNIs and haematomas (although many CNIs are non-permanent).
Periprocedural death rates are similar between procedures, and periprocedural stroke/death rates in favour of CEA are likely due to differences in stroke numbers ( Figure 2B,D) . MI rates have remained similar most likely reflecting factors other than proceduralist skill or experience ( Figure 2C ). The high rate of periprocedural MI during the SAPPHIRE trial is likely due to patients being high risk.
| Systematic reviews
Several systematic reviews have strengthened the data surrounding Tapered stents, characterized by a larger diameter proximally and narrow diameter distally, are designed to mimic the progressive narrowing of the ICA. Evidence on tapered vs non-tapered stents is poor, with only one published retrospective study in the literature.
| S TENTS
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This revealed no difference in the 30-day stroke rates between tapered and non-tapered groups; however, restenosis at follow-up was more common with non-tapered stents (2.6% vs 0%; P = 0.03).
| Stent models
Several carotid artery stents have been approved by the FDA (Table 2 ). The first self-expanding stent was the Carotid Wallstent (Boston Scientific, Mountain View, CA). With the exception of the Carotid Wallstent, which is made from elgiloy, the majority of selfexpanding carotid artery stents are made of nitinol. When exposed to the temperature of the human body, the thermal properties of nitinol stents allow them to achieve a predefined shape, whereas the expansion of the Carotid Wallstent relies on a spring-like action as its delivery sheath is withdrawn.
The Acculink nitinol stent was the first to be approved following the ARCHeR trial. 50 Following approval of the Guidant Acculink stent and Accunet EPD, the CAPTURE study commenced. 51 This prospective, multicentre registry of 3500 patients assessed outcomes of CAS using these devices in the same patients in the noninvestigational setting. Following CREST, the FDA approved the use of the Acculink stent with the Accunet EPD in standard-risk patients with either symptomatic or asymptomatic carotid artery stenosis. American registry indicated that stents were typically used with their respective EPD systems (78.2%). 52 The most commonly used devices were the Acculink/Accunet, Xact/Emboshield (Abbott) and the Precise/Angioguard (Cordis, Milpitas, CA) stents. Devices seldom used were the Protégé/SpiderFx (Medtronic, Plymouth, MN) (3.7%) and Carotid Wallstent/Filterwire (Boston Scientific, Natick, MA) (1.8%). Non-significant differences were seen with respect to rates of in-hospital stroke and death between the three most commonly used devices.
| TECHNI Q U E S
| Embolic protection
Embolic complications of endovascular therapy have prompted the development of EPDs. Manipulation of sheaths and catheters in an atheromatous arch, wiring and delivery of devices across the lesion, balloon expansion, stent deployment and EPD removal may all lead to embolization. Cerebral protection was first described in 1987 by
Theron et al using temporary distal balloon occlusion (TDBO). 53 In 1990, a triple co-axial catheter was developed. 54 Numerous EPDs have been designed using filters and guidewire-attached balloons.
Distal filter embolic protection devices (f-EPDs) and proximal embolic protection devices (p-EPDs) are the two most commonly used EPDs. 52 EPDs were used in most RCTs comparing CAS to CEA; however, frequency of use and type of device varied considerably.
Complications associated with EPDs include vasospasm and arterial dissection. 41 Figure 3 demonstrates deployment of an f-EPD during CAS for a young patient with carotid stenosis secondary to fibromuscular dysplasia.
| Embolic protection vs no protection
It is not clear whether cerebral protection is beneficial, with singlecentre RCTs using popular devices suggesting that EPDs provide no benefit. 55, 56 The SPACE trial drew similar conclusions. 41 In comparison, a multicentre prospective registry of 1483 patients reported that patients treated with EPDs had lower rates of ipsilateral stroke (1.7% vs 4.1%; P = 0.007) and non-fatal strokes/deaths (2.1% vs 4.9%; P = 0.004). 57 An even larger registry of 11 243 patients supported this argument, reporting fewer periprocedural strokes and deaths with EPD use (2.23% vs 5.29%; P < 0.0001). 58 A systematic review of 2357 patients reported lower periprocedural stroke/death rates in patients who received cerebral protection, although death rates were almost identical. 
| EPD techniques
P-EPDs achieve cerebral protection by occluding vessels proximal to the stenosis and stagnating flow, while F-EPDs entrap embolic material that becomes dislodged during the procedure. P-EPDs There are no large multicentre RCTs comparing p-EPDs and fEPDs; however, published studies generally support proximal protection. Data from three small RCTs and four observational studies were pooled in a recent meta-analysis, with the incidence of new ischaemic lesions/patient on diffusion-weighted magnetic resonance imaging (dw-MRI) significantly lower in the proximal balloon occlusion group. 62 Despite potentially being associated with subtle neurocognitive defects, the significance of these lesions is unclear as many are asymptomatic and disappear over time. 63 Castro-Afonso et al reported fewer embolic events with f-EPDs. 64 A large retrospective analysis (n = 10 264) reported no difference in the rates of stroke/death in-hospital or within 30 days between p-EPD and f-EPD cohorts; however, p-EPD use was infrequent making this difficult to interpret. 61 Another retrospective analysis of 3,160 patients also reported no significant difference in 30-day outcomes with a range of devices, although several limitations were present.
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A technique combining the use of p-EPDs and f-EPDs (double protection) has also been described. A single-centre study (n = 78) reported a significantly lower incidence and number of postprocedure ischaemic lesions on dw-MRI with double protection compared to f-EPD. 65 
| S PECIFI C PATIENT P OPUL ATI ON S
| Previous CEA
Restenosis rates following CEA range from 10% to 25%. 66 Redo CEA has an increased potential for CNIs and also carries an increased stroke risk compared with primary CEA. 66 There are no high-quality data guiding management of these patients. A systematic review and meta-analysis of 4399 patients from 50 studies reported no differences in 30-day rates of stroke/TIA/MI or long-term stroke rates between CAS and CEA groups for patients with restenosis. 67 CNIs were more common with CEA, but recurrent restenosis was more common with CAS (both P < 0.05).
Another review of 1132 patients from 13 studies reported comparable results, with similar perioperative stroke/death rates between groups although restenosis rates were also similar. 68 A 
| Cervical radiotherapy
Cervical radiotherapy accelerates the development of carotid artery stenosis, with the RR of TIA or ischaemic stroke at least doubled. 70 The effects of radiotherapy can make surgery high risk;
however, high-quality trials comparing CAS to CEA are lacking.
Restenosis is the primary concern of CAS. A prospective study of 150 high-risk patients reported significantly higher rates of restenosis at 3 years with CAS in patients with previous c-XRT compared to those without (80% vs 26%; P < 0.05). 71 Other studies have reported no difference in restenosis rates in patients who have received c-XRT. 72 A systematic review and meta-analysis of 533 patients comparing CAS against CEA in patients with previous c-XRT reported similar rates of perioperative stroke/TIA between groups; however, long-term stroke/TIA (P = 0.014) and restenosis (P < 0.003) were more likely with CAS. CNIs were more common with CEA; however, long-term rates of cerebrovascular events favoured CEA (P = 0.014). 73 No high-quality trials have evaluated the utility of medical therapy in this cohort.
| C A S IN OTHER S E T TING S
| Acute stroke and tandem lesions
Carotid artery stenosis is a major cause of stroke, usually due to unstable atheroma resulting in acute thrombosis or embolization. Stenting requires antiplatelet therapy (often in addition to intravenous (IV) thrombolysis), predisposing patients to intracranial haemorrhage. Prethrombectomy angioplasty is an alternative to stenting, however is associated with its own complications. 26 Evidence guiding management of tandem lesions is poor.
Thrombolysis produces poorer outcomes with ICA and cerebral vessel tandem lesions compared to single-vessel occlusion. IV thrombolysis, whereas subgroup analysis of the MR CLEAN trial revealed no significant difference between groups. 76, 77 A multicentre retrospective analysis (n = 170) reported an incidence of 9% for symptomatic intracranial haemorrhages (sICH) with CAS plus ECR for tandem occlusions. 79 In 77% of patients, a Thrombolysis in Cerebral Infarction (TICI) score of ≥2b was achieved; however, mortality was high (19%) and only 36% of patients had a modified Rankin score of ≤2 at follow-up.
A meta-analysis of 11 studies reported revascularization and sICH rates of 83% and 4%, respectively, in emergency CAS. 80 At 3 months, favourable clinical outcomes were seen in 46% of cases and mortality was 13%. A 2017 review reported TICI ≥ 2b revascularization was achieved in 79% of patients with tandem occlusions. Treatment options for acute extracranial ICA occlusion include IV thrombolysis, CEA or endovascular therapy. There is no good evidence suggesting which of these is best. Acute ICA occlusion has a poor prognosis and mortality is as high as 73%. 83 IV thrombolysis is associated with poor outcomes in these patients. 84 A prospective study of 201 patients with acute ICA occlusion treated with IAT, endovascular mechanical therapy or a combination of both reported better recanalization rates with mechanical approaches compared with pharmacological thrombolysis alone (86%/82% with/without thrombolytics vs 47%; P < 0.001). 85 These patients also achieved better neurological outcomes, although still poor. Mortality was 31%
and favourable neurological outcomes at 3 months were achieved in only 28% of patients.
Studies evaluating CAS in acute ICA occlusion are lacking.
Published retrospective studies are small and heterogeneous.
Pooled data from six retrospective studies compared CAS to IAT.
Stenting resulted in a higher recanalization rates (87% vs 48%; P = 0.001), more favourable outcomes (68% vs 15%; P < 0.001) and lower mortality (18% vs 41%; P = 0.048). 82 Other retrospective studies have reported recanalization rates and sICH of 36.4%-100%
and 6%-24.8%, respectively. Neurological outcomes varied dramatically and were generally poor. 86, 87 Similar outcomes have been reported with emergent CEA.
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There is currently a significant lack of data comparing expedited CEA to expedited CAS in patients who are recently symptomatic.
Less than half of the RCTs comparing CAS to CEA reported on the timing of intervention. Of those that did, the overwhelming majority of interventions were performed more than 14 days after the symptomatic event. CREST reported the shorted median interval time at 22 days for CEA and 18 days for CAS. In fact, the mean delay in all
RCTs was over 14 days and even over 1 month in all RCTs except two. 89 The lack of robust data investigating the safety and efficacy of CAS in the acute/peri-stroke period is particularly significant given the routine use of ECR for stroke.
Nevertheless, pooled data from SPACE, EVA-3S and ICSS (n = 2839) suggested that the timing of intervention following symptomatic events may be clinically important. 90 The highest rates of stroke/death for CAS occurred when intervention was performed within 7 days of the qualifying symptomatic event. Stroke/death rates for CEA during this time were at their lowest. Alternatively, performing CAS >14 days after the qualifying event produced the lowest stroke/death rates in this group. Stroke/death rates for CEA during this time were at their highest. However, as this study did not include patients presenting acutely with tandem lesions or internal carotid artery occlusion, it cannot be extrapolated to patients presenting with acute stroke. In recently symptomatic patients with a 50%-99% stenosis who present with adverse anatomical features or medical comorbidities that are considered to make them "high risk for CEA," CAS should be considered, provided the documented procedural death/stroke rate is <6% When revascularization is indicated in "average surgical risk" patients with symptomatic carotid disease, CAS may be considered as an alternative to surgery, provided the documented procedural death/stroke rate is <6%. When decided, it is recommended to perform revascularization of symptomatic 50%-99% carotid stenoses as soon as possible, preferably within 14 d of symptom onset 
| CURRENT G U IDELINE S
CAS guidelines are not uniform and have not been updated with the most recent data ( Table 4 ). The American Stroke Association's recommendations differ depending on the severity of stenosis and vascular risk factors. 99 Citing a lack of evidence, the 2011 NICE guidelines argue that CAS for asymptomatic stenosis should only be used in specific circumstances; however, CAS for symptomatic stenosis is supported. 100 The Society for Vascular Surgery generally recommends CEA over CAS in patients who are not surgically high risk. 101 The
European Society for Vascular Surgery advocate for the use of CAS as an alternative to CEA in patients who are high risk and/or provided that the documented procedural stroke/death risk is <6%. SPACE-2, CREST-2, ACST-2 and ECST-2 will provide crucial evidence to address these gaps in the literature (Table 5) .
| CON CLUS ION
Stroke is a major contributor to the global health burden. Many strokes occur secondary to carotid artery stenosis. CAS has become an alternative treatment for carotid artery stenosis, and multiple trials have compared CAS to CEA. Periprocedural stroke is more commonly associated with CAS; however, MI is more commonly associated with CEA. Long-term outcomes are comparable. The role of CAS to treat carotid artery stenosis is widely debated and guidelines are heterogenous. CAS can be performed using different techniques, equipment and medications, and it has not yet been established which combination of these produces the best outcomes for specific indications.
Further high-quality RCTs are required to address these shortcomings and controversies, in order to provide a stronger basis for evidence-based management and consistent practice guidelines. 
